/PRNewswire/ The global drug discovery outsourcing market size is estimated to grow by USD 1.79 bn from 2024-2028, according to Technavio. The market is.
OPM Publishes Its Annual Results for 2023 and Provides an Update on Its Clinical Developments marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.
Oncodesign Precision Medicine: OPM Publishes Its Annual Results for 2023 and Provides an Update on Its Clinical Developments finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
26.03.2024 - Regulatory News: Oncodesign Precision Medicine (OPM) (ISIN: FR001400CM63; Mnemonic: ALOPM), a biopharmaceutical company specializing in precision medicine for the treatment of resistant and metastatic cancer, has published its financial results for .
On Tuesday, investment group Eurazeo announced that it had acquired a stake in Oncodesign Services, a company specializing in drug discovery and pre-clinical services in oncology and.